



SDI Review Form 1.6

| | |
|--------------------------|--|
| Journal Name: | Journal of Pharmaceutical Research International |
| Manuscript Number: | Ms_JPRI_64130 |
| Title of the Manuscript: | Survival and Biomarkers of COVID-19 Patients Treated with remdesivir and Favipiravir in ICU during the Peak of Pandemic: A Single Center Study in Bangladesh |
| Type of the Article | Original Research Article |

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<http://www.sciencedomain.org/journal/10/editorial-policy>

PART 1: Review Comments

| | Reviewer's comment | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|-------------------------------------|--|---|
| Compulsory REVISION comments | Author's needs to clarify the individual variations of each patient, as some of them might have better immune response in comparison to other's. | |
| Minor REVISION comments | Individual variations and health parameters studied during the study should be provided as supplementary material. | |
| Optional/General comments | - | |

PART 2:

| | Reviewer's comment | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|--|--|---|
| Are there ethical issues in this manuscript? | <i>(If yes, Kindly please write down the ethical issues here in details)</i> | |

Reviewer Details:

| | |
|----------------------------------|--|
| Name: | Archisman Mahapatra |
| Department, University & Country | Banaras Hindu University, India |